Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim therapy is an implantable system that delivers electrical pulses to carotid baroreceptors to rebalance autonomic nervous system signaling and improve symptoms in heart failure patients.
Company updates commonly cover Barostim commercialization in the United States and Europe, FDA approval and Breakthrough Device history, CE Mark status for heart failure and resistant hypertension in the European Economic Area, clinical data from heart failure studies, reimbursement and coding developments, quarterly operating results, financing activity and board governance matters.
CVRx has appointed Robert John as Chief Revenue Officer, effective June 27. John will lead the US sales team to maximize the impact of Barostim therapy on heart failure patients and establish it as the standard of care in the US. Robert John brings over 25 years of experience in the medical device industry, having previously held significant leadership roles at Abbott and St. Jude Medical. His latest role was Divisional Vice President and General Manager of Cardiac Rhythm Management EMEA at Abbott. John's extensive expertise in building high-performing sales teams and launching heart failure therapies is expected to accelerate CVRx's commercial momentum. John is excited to contribute to CVRx's mission and expand the reach of Barostim therapy.
CVRx, a commercial-stage medical device company, announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 5, 2024. The presentation is scheduled for 8:40am Central Time and will be available via live audio webcast on the company's investor relations page.
CVRx, a commercial-stage medical device company, announced the addition of three key executives to its senior leadership team. Dr. Philip B. Adamson will join as Chief Medical Officer, Bonnie Handke as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund as Senior Vice President of Global Clinical Affairs. These new roles aim to drive the adoption of CVRx's Barostim™ therapy and expand patient access. Dr. Adamson brings nearly three decades of experience in heart failure from Abbott Laboratories, Bonnie Handke comes with extensive experience from Medtronic, and Jennifer Englund has a strong background in leading clinical strategies in the medical device industry. The new hires will focus on making Barostim therapy a standard of care for heart failure patients.
CVRx reported solid financial and operating results for the first quarter of 2024, with total revenue reaching $10.8 million, a 35% increase over the prior year. U.S. Heart Failure revenue grew by 43%, active implanting centers in the U.S. increased by 56%, and gross profit rose by 38%. However, there was a significant increase in SG&A expenses, leading to a net loss of $22.2 million. The company's CEO is addressing commercial execution challenges to scale the business effectively.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.